Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)

Inclusion Criteria: * Signature of the subject's informed consent prior to any trial-related activity. * Age between 18 and 35 years (both inclusive). * Regular menstrual cycle, from 25 to 35 days (both inclusive). * Absence of physical and psychological illness at the time of donation at the discretion of the investigator. * BMI 18-28 kg/m2 (both inclusive) at the time of donation. * No personal or family history of interest at the discretion of the investigator. * Normal uterus and ovaries, without organic pathology. * No polycystic ovaries. * Antral follicle count greater than 12 in the sum of the two ovaries at the time of the screening visit. * Normal karyotype. * Negative infectious disease screening (Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus and Syphilis). * General analysis with hemogram, hemostasis and biochemistry with parameters within normality. Exclusion Criteria: * Concurrent participation in another clinical trial. * Previous participation in this clinical trial. * Use of long-term hormonal contraception (hormonal IUD or subcutaneous implants) at least 1 month prior to enrollment. * Any systemic or metabolic disorder (i.e.: diabetes...) that contraindicates the use of gonadotropins. * Personal history of thrombophlebitis and thromboembolic phenomena and hypertension. * Severe hepatic insufficiency, cardiovascular disease * Suspicion or evidence of breast malignancy or hormone-dependent genital organs. * Known hypersensitivity to AMP or its excipients * Any reason for exclusion from the oocyte donation program.